AARD Stock Analysis: Buy, Sell, or Hold?
AARD - Aardvark Therapeutics, Inc. Common Stock
$4.23
0.15 (3.68%)
▲
5d:
+10.16%
30d:
-6.21%
90d:
+4.06%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When AARD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AARD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: AARD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: AARD is currently trading at $4.23, which is considered slightly high relative to its 30-day fair value range of $3.71 to $4.32.
Technical Outlook: Technically, AARD is in a strong downtrend. Immediate support is located at $3.40, while resistance sits at $4.45. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: AARD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.44 (+265.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AARD is in a strong downtrend. Immediate support is located at $3.40, while resistance sits at $4.45. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: AARD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.44 (+265.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.71 -
$4.32
Company Quality Score
54/100
(HOLD)
Options IV Signal
7th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
87.5%
All Signals
- BULLISH: Options cheap (IV 7th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 265.1% below Wall St target ($15.44)
Trading Range Analysis
30-Day Trading Range
$3.71 -
$4.32
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.94
(22.2%)
Support & Resistance Levels
Support Level
$3.40
Resistance Level
$4.45
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.31
Wall Street Target
$15.44
(+265.1%)
Share & Embed Analysis
Last updated: June 23, 2026 7:04 PM ET
Data refreshes hourly during market hours. Next update: 8:04 PM
Data refreshes hourly during market hours. Next update: 8:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AARD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
